Condition
Pulmonary Arterial Hypertension Clinical Trials
Studies of pulmonary arterial hypertension, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 135Pulmonary Hypertension, Pulmonary Arterial Hypertension
Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated.
- Trial name
- AIPHY (NCT05566002)
- Testing
- Right heart catheterization
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
Researchers are looking for other ways to treat people in India with pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH).
- Trial name
- NCT07600723
- Testing
- Sotatercept, Background PAH Therapy
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea
The purpose of this study is to evaluate how safe Opsynvi (macitentan/tadalafil fixed-dose combination) is in adult participants with pulmonary arterial hypertension under routine clinical practice in Korea.
- Trial name
- Opsynvi RMP (NCT07890285)
- Volunteers
- 333 people
- Sponsor
- Janssen Korea, Ltd., Korea
Pulmonary Arterial Hypertension
Spironolactone for Pulmonary Arterial Hypertension
Background: High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. In spite of recent advances in treatment, the death rate remains unacceptably high.
- Trial name
- NCT01712620
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Pulmonary Arterial Hypertension
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
- Trial name
- NCT06274801
- Testing
- Seralutinib, Gereic Dry Powder Inhaler
- Where
- 120 sites in United States, Argentina and 28 more
- Volunteers
- 330 people
- Sponsor
- Gossamer Bio USA, Inc.
Pulmonary Arterial Hypertension
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.
- Trial name
- PALM-PAH (NCT07481981)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 39 sites in United States, Argentina and 6 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).
- Trial name
- ROCSTAR (NCT07175038)
- Testing
- ROC-101
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AllRock Bio, Inc.
PAH, Pulmonary Hypertension
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03683186
- Testing
- Ralinepag
- Where
- 190 sites in United States, Argentina and 31 more
- Volunteers
- 1,000 people
- Sponsor
- United Therapeutics
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to…
- Conditions
- Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury
- Trial name
- NCT07613099
- Testing
- [18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)
The goal of this study is to learn about the safety of sotatercept and how well Japanese children tolerate it, when taken along with standard (usual) pulmonary arterial hypertension (PAH) treatment.
- Trial name
- NCT07646860
- Testing
- Sotatercept
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Completed, with results posted
All –Pulmonary Arterial Hypertension
Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test
Evaluate for accuracy and reproducibility of data collected via the participant-operated Walk.Talk.Track. (WTT) app combined with Apple Watch during in-clinic, technician proctored 6MWT's.
- Trial name
- DynAMITE (NCT03893500)
- Testing
- Home-based 6 minute walk test
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Stanford University
Pulmonary Arterial Hypertension
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
The objectives of this study are to evaluate the safety of RT234 and the effects of RT234 on exercise capacity as assessed by Cardiopulmonary Exercise Testing (CPET) and six minute walk testing (6MWT) as well as exertional…
- Trial name
- VIPAH-PRN_2B (NCT04266197)
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)
- Where
- 26 sites in United States
- Volunteers
- 42 people
- Sponsor
- Respira Therapeutics, Inc.
Pulmonary Arterial Hypertension
A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)
This local Phase 3 study is planned to confirm the efficacy and safety in Japanese PAH participants. The primary population of this study is Japanese PAH participants with World Health Organization Functional Class (WHO FC) II or…
- Trial name
- NCT05818137
- Testing
- Sotatercept
- Where
- 17 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus maximum…
- Trial name
- ZENITH (NCT04896008)
- Testing
- Sotatercept
- Where
- 57 sites in United States, Australia and 10 more
- Volunteers
- 173 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension
A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the effect of macitentan on hemodynamic measures at Week 24 in pediatric populations.
- Trial name
- NCT05167825
- Testing
- Macitentan
- Where
- 11 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Janssen Pharmaceutical K.K.